Chen Xiu-Ke, Wei Ying-Hui, Yao Jin-Na, Zhao Yan-Min, Shang Xiao-Guang, Li Fan-Zhu
College of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Zhongguo Zhong Yao Za Zhi. 2013 Feb;38(4):548-52.
To prepare chitosan-modified tripterygium glycoside nanoparticles (LMWC-TG-PLA-NPs), and assess its renal targeting property in rats.
Chitosan-modified tripterygium glycoside nanoparticles (LMWC-TG-PLA-NPs) were prepared by modified spontaneous emulsification solvent evaporation method, and modified with 50% deacetylated low molecular weight chitosan (LMWC). The shape of nanoparticles was observed under a transmission electron microscope. The mean diameter of nanoparticles was measured by particle size analyzer. The drug encapsulation efficiency and drug loading were measured by centrifuge method. The in vitro release behavior was studied with dialysis bags. Renal microdialysis technique and renal artery administration technique were combined to study the renal targeting property of nanopartcles. LMWC-TG-PLA-NPs were administrated in rats by tail vein injection (TVI) and renal artery administration (RAA), respectively, with TG-PLA-NPs as the control group. Renal dialysis fluid was regularly collected to determine the drug concentration in the dialysis fluid, map drug concentration-time curves, and calculate AUC ratio in kidneys through the two injection approaches as the renal targeting parameter (RTP), in order to assess the renal targeting property of LMWC-TG-PLA-NPs.
The prepared LMWC-TG-PLA-NPs looked smooth and round. Their average diameter, polydispersity index, encapsulation efficiency and drug loading were (207.6 +/- 3.4) nm, (0.078 +/- 0.009)%, (61.83 +/- 2.43)%, and (10.70 +/- 0.37)%, respectively. The pH 7.4 PBS buffer solution containing 20% ethanol showed obvious sustained release behavior. LMWC-TG-PLA-NPs showed a RTP of 71.97%, which was 3.6 times of TG-PLA-NPs of the control group.
The prepared LMWC-TG-PLA-NPs showed high drug encapsulation efficiency and drug loading, with obvious sustained release characteristics and renal targeting property. LMWC-TG-PLA-NPs are expected to become a new type vector for reducing toxic and side effects of tripterygium glycoside. Meanwhile, a new method is established for assessing renal targeting property with AUC ratio in kidneys after administrated through caudal veins and renal arteries as the renal targeting parameter.
制备壳聚糖修饰的雷公藤多苷纳米粒(LMWC-TG-PLA-NPs),并评价其在大鼠体内的肾靶向性。
采用改良的自发乳化溶剂挥发法制备壳聚糖修饰的雷公藤多苷纳米粒(LMWC-TG-PLA-NPs),并用50%脱乙酰化低分子量壳聚糖(LMWC)进行修饰。在透射电子显微镜下观察纳米粒的形态。用粒度分析仪测定纳米粒的平均粒径。采用离心法测定药物包封率和载药量。用透析袋研究体外释放行为。将肾微透析技术与肾动脉给药技术相结合,研究纳米粒的肾靶向性。分别通过尾静脉注射(TVI)和肾动脉给药(RAA)将LMWC-TG-PLA-NPs给予大鼠,以TG-PLA-NPs作为对照组。定期收集肾透析液,测定透析液中的药物浓度,绘制药物浓度-时间曲线,并通过两种注射途径计算肾脏中的AUC比值作为肾靶向参数(RTP),以评价LMWC-TG-PLA-NPs的肾靶向性。
制备的LMWC-TG-PLA-NPs外观光滑圆润。其平均粒径、多分散指数、包封率和载药量分别为(207.6±3.4)nm、(0.078±0.009)%、(61.83±2.43)%和(10.70±0.37)%。含20%乙醇的pH 7.4 PBS缓冲溶液呈现明显的缓释行为。LMWC-TG-PLA-NPs的肾靶向参数为71.97%,是对照组TG-PLA-NPs的3.6倍。
制备的LMWC-TG-PLA-NPs具有较高的药物包封率和载药量,具有明显的缓释特性和肾靶向性。LMWC-TG-PLA-NPs有望成为降低雷公藤多苷毒副作用的新型载体。同时,建立了一种以尾静脉和肾动脉给药后肾脏中的AUC比值为肾靶向参数评价肾靶向性的新方法。